Lindsey Miller
Nurse Practitioner · Hattiesburg, MSNPI 1770173114
Payments from drug & device makers
Across 741 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Mylan Specialty L.p.$1K
- Boehringer Ingelheim$919
- Grifols USA, LLC$860
- Sanofi$712
- plus $5K from 31 others
What the payments were for
- Food & beverage$13,036100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 120 | $2,618 |
| GSK | 166 | $1,904 |
| Mylan Specialty L.p. | 53 | $1,002 |
| Boehringer Ingelheim | 56 | $919 |
| Grifols USA, LLC | 45 | $860 |
| Sanofi | 33 | $712 |
| United Therapeutics Corporation | 28 | $506 |
| Regeneron Healthcare Solutions, Inc. | 20 | $468 |
| Viatris Specialty LLC | 32 | $454 |
| Electromed, Inc. | 25 | $339 |
| Jazz Pharmaceuticals Inc. | 14 | $297 |
| Insmed, Inc. | 18 | $284 |
| Baxter Healthcare | 10 | $281 |
| Actelion Pharmaceuticals US, Inc. | 14 | $274 |
| Mallinckrodt Hospital Products Inc. | 12 | $251 |
| Amgen | 8 | $198 |
| Axsome Therapeutics, Inc. | 7 | $188 |
| Merck | 8 | $167 |
| Shionogi Inc | 10 | $165 |
| Verona Pharma, Inc. | 10 | $163 |
| ANI Pharmaceuticals, Inc. | 7 | $151 |
| Inspire Medical Systems, Inc. | 7 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $135 |
| Bayer | 5 | $75 |
| Pulmonx Corporation | 3 | $72 |
| Philips North America LLC | 3 | $59 |
| La Jolla Pharmaceutical Company | 3 | $52 |
| Pfizer | 3 | $52 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $42 |
| Inari Medical, Inc. | 3 | $41 |
| Vifor Pharma, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| Chiesi USA, Inc. | 2 | $29 |
| AbbVie | 1 | $18 |
| Liquidia Technologies, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,036 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 213 | $167,949 |
| Spiriva RespimatTiotropium Bromide | 62 | $51,100 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $47,269 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $26,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $16,844 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $15,925 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 64 | $13,849 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $12,828 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $11,480 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 254 | $11,247 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $10,127 |
| BreynaBudesonide/Formoterol Fumarate | 24 | $7,224 |
| Arnuity ElliptaFluticasone Furoate | 31 | $6,482 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $5,690 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $3,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,904 | $233,181373 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $919 | $74,055101 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $2,618 | $49,143109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Other nurse practitioner in Hattiesburg
- Kaylon LewisHattiesburg$25K
- Brittany RobertsHattiesburg$5K
- Sarah KellyHattiesburg$5K
- Christina TreppendahlRidgeland$673K
- Catherine WellsJackson$75K
- Jo Anna WarrenJackson$73K
- Marisa StringerBiloxi$68K
- Sara KlausFlowood$48K
- Micaela PerkinsOxford$32K
- Michelle TharpJackson$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.